Login Register Cart 0
Generic placeholder image

Current Pharmacogenomics and Personalized Medicine

Editor-in-Chief

ISSN (Print): 1875-6921
ISSN (Online): 1875-6913

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Effects of Alantolactone on Stemness Genes Expression and Epithelial-Mesenchymal Transition (EMT) in Breast Cancer via STAT3 Suppression

Author(s): Shiva Gholizadeh-Ghaleh Aziz*, Saiedeh Kashefi and Naser Khalaji

Volume 19, Issue 1, 2022

Published on: 11 April, 2022

Page: [21 - 30] Pages: 10

DOI: 10.2174/1875692119666220211154735

Price: $65

Abstract

Background: To reduce the side effects of conventional chemotherapy drugs, new herbal remedies, such as alantolactone, can be used.

Objective: We evaluated the association between stemness and EMT (Epithelial- Mesenchymal Transition) process in triple-negative breast cancer cells treated with alantolactone that targets STAT3.

Methods: The MDA-MB-231 cell line was used as one of the triple-negative breast cancer cell lines. MTT assay was used to evaluate cell viability and alantolactone dose at threetime points of 24, 48, and 72 hours, and three doses, i.e., 1, 0.1, and 0.01 μM of alantolactone were used to evaluate cellular behavior in proliferative and invasion pathways, respectively. A scratch test was also performed to evaluate the invasive power of cancer cells. Real- time PCR was used to evaluate the expression of regular genes by cancerous cell proliferation, STAT3 NANOG, SOX-2, and E-cadherin metastasis.

Results: It was observed that increasing the dose of alantolactone decreased proliferation and metastasis rate. The three doses selected for the cell culture study did not differ significantly from the control group regarding apoptosis-inducing abilities at desired time intervals. Expression of SOX-2, STAT3, and NANOG in the treated cells decreased with increasing dose of the alantolactone, whereas expression of E-cadherin was found to be increased.

Conclusion: Alantolactone through the STAT3 signaling pathway affects the expression of E-cadherin, NANOG, and SOX2 genes, inhibiting the EMT process and subsequent stemness, and may potentially be used in therapeutics for cancer patients.

Keywords: STAT3 suppression, epithelial to mesenchymal transition (EMT), Alantolactone (ALT), breast cancer, MTT assay, estrogen receptors (ER).

« Previous Next »
[1]
Sinn HP, Kreipe H. A brief overview of the WHO classification of breast tumors, 4th edition, focusing on issues and updates from the 3rd edition Breast Care (Basel) 2013 8(2): 149-54.
[http://dx.doi.org/10.1159/000350774] [PMID: 24415964]
[2]
Seyfried TN, Huysentruyt LC. On the origin of cancer metastasis. Crit Rev Oncog 2013; 18(1-2): 43-73.
[http://dx.doi.org/10.1615/CritRevOncog.v18.i1-2.40] [PMID: 23237552]
[3]
Li W, Kang Y. Probing the fifty shades of EMT in metastasis. Trends Cancer 2016; 2(2): 65-7.
[http://dx.doi.org/10.1016/j.trecan.2016.01.001] [PMID: 27042694]
[4]
Jolly MK, Ware KE, Gilja S, Somarelli JA, Levine H. EMT and MET: Necessary or permissive for metastasis? Mol Oncol 2017; 11(7): 755-69.
[http://dx.doi.org/10.1002/1878-0261.12083] [PMID: 28548345]
[5]
Du B, Shim JS. Targeting Epithelial-Mesenchymal Transition (EMT) to overcome drug resistance in cancer. Molecules 2016; 21(7): E965.
[http://dx.doi.org/10.3390/molecules21070965] [PMID: 27455225]
[6]
Kamran MZ, Patil P, Gude RP. Role of STAT3 in cancer metastasis and translational advances. BioMed Res Int 2013; 2013: 421821.
[http://dx.doi.org/10.1155/2013/421821] [PMID: 24199193]
[7]
Wendt MK, Balanis N, Carlin CR, Schiemann WP. STAT3 and epithelial-mesenchymal transitions in carcinomas. JAK-STAT 2014; 3(1): e28975.
[http://dx.doi.org/10.4161/jkst.28975] [PMID: 24843831]
[8]
Wang Y-J, Herlyn M. The emerging roles of Oct4 in tumor-initiating cells. Am J Physiol Cell Physiol 2015; 309(11): C709-18.
[http://dx.doi.org/10.1152/ajpcell.00212.2015] [PMID: 26447206]
[9]
Carpenter RL, Lo H-W. STAT3 target genes relevant to human cancers. Cancers (Basel) 2014; 6(2): 897-925.
[http://dx.doi.org/10.3390/cancers6020897] [PMID: 24743777]
[10]
Migita T, Ueda A, Ohishi T, et al. Epithelial-mesenchymal transition promotes SOX2 and NANOG expression in bladder cancer. Lab Invest 2017; 97(5): 567.
[http://dx.doi.org/10.1038/labinvest.2017.17] [PMID: 28240746]
[11]
Dai X, Ge J, Wang X, Qian X, Zhang C, Li X. OCT4 regulates epithelial-mesenchymal transition and its knockdown inhibits colorectal cancer cell migration and invasion. Oncol Rep 2013; 29(1): 155-60.
[http://dx.doi.org/10.3892/or.2012.2086] [PMID: 23076549]
[12]
Blinka S, Rao S. Nanog expression in embryonic stem cells - An ideal model system to dissect enhancer function. BioEssays 2017; 39(12): 1700086.
[http://dx.doi.org/10.1002/bies.201700086] [PMID: 28977693]
[13]
Nagata T, Shimada Y, Sekine S, et al. KLF4 and NANOG are prognostic biomarkers for triple-negative breast cancer. Breast Cancer 2017; 24(2): 326-35.
[http://dx.doi.org/10.1007/s12282-016-0708-1] [PMID: 27300169]
[14]
Gao H, Teng C, Huang W, Peng J, Wang C. SOX2 Promotes the epithelial to mesenchymal transition of esophageal squamous cells by modulating slug expression through the activation of STAT3/HIF-α Signaling. Int J Mol Sci 2015; 16(9): 21643-57.
[http://dx.doi.org/10.3390/ijms160921643] [PMID: 26370982]
[15]
Cetin I, Topcul M. Triple negative breast cancer. APJCP 2014; 15(6): 2427-31.
[PMID: 24761842]
[16]
Ijaz S, Akhtar N, Khan MS, et al. Plant derived anticancer agents: A green approach towards skin cancers. Biomed Pharmacother 2018; 103: 1643-51.
[http://dx.doi.org/10.1016/j.biopha.2018.04.113]
[17]
Ouyang L, Luo Y, Tian M, et al. Plant natural products: From traditional compounds to new emerging drugs in cancer therapy. Cell Prolif 2014; 47(6): 506-15.
[http://dx.doi.org/10.1111/cpr.12143] [PMID: 25377084]
[18]
Maryam A, Mehmood T, Zhang H, Li Y, Khan M, Ma T. Alantolactone induces apoptosis, promotes STAT3 glutathionylation and enhances chemosensitivity of A549 lung adenocarcinoma cells to doxorubicin via oxidative stress. Sci Rep 2017; 7(1): 6242.
[http://dx.doi.org/10.1038/s41598-017-06535-y] [PMID: 28740138]
[19]
Chun J, Li RJ, Cheng MS, Kim YS. Alantolactone selectively suppresses STAT3 activation and exhibits potent anticancer activity in MDA-MB-231 cells. Cancer Lett 2015; 357(1): 393-403.
[http://dx.doi.org/10.1016/j.canlet.2014.11.049] [PMID: 25434800]
[20]
Babaei G, Aliarab A, Abroon S, Rasmi Y, Aziz SG. Application of sesquiterpene lactone: A new promising way for cancer therapy based on anticancer activity. Biomedicine & pharmacotherapy 2018; 106: 239-46.
[http://dx.doi.org/10.1016/j.biopha.2018.06.131]
[21]
Abubaker K, Luwor RB, Escalona R, et al. Targeted disruption of the JAK2/STAT3 pathway in combination with systemic administration of paclitaxel inhibits the priming of ovarian cancer stem cells leading to a reduced tumor burden. Front Oncol 2014; 4: 75.
[http://dx.doi.org/10.3389/fonc.2014.00075] [PMID: 24782986]
[22]
Vitale G, Zappavigna S, Marra M, et al. The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells. Biotechnol Adv 2012; 30(1): 169-84.
[http://dx.doi.org/10.1016/j.biotechadv.2011.08.001] [PMID: 21871555]
[23]
Kim SR, Seo HS, Choi HS, et al. Trichosanthes kirilowii ethanol extract and cucurbitacin D Inhibit cell growth and induce apoptosis through inhibition of STAT3 activity in breast cancer cells. Evid Based Complement Alternat Med 2013; 2013: 975350.
[24]
Walker SR, Xiang M, Frank DA. Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer. Mol Cell Endocrinol 2014; 382(1): 616-21.
[http://dx.doi.org/10.1016/j.mce.2013.03.010] [PMID: 23531638]
[25]
Marotta LL, Almendro V, Marusyk A, et al. The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24− stem cell-like breast cancer cells in human tumors. J Clin Invest 2011; 121(7): 2723-35.
[http://dx.doi.org/10.1172/JCI44745] [PMID: 21633165]
[26]
Ara T, Declerck YA. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 2010; 46(7): 1223-31.
[http://dx.doi.org/10.1016/j.ejca.2010.02.026]
[27]
Lee HJ, Seo NJ, Jeong SJ, et al. Oral administration of penta-O-galloyl-β-D-glucose suppresses triple-negative breast cancer xenograft growth and metastasis in strong association with JAK1-STAT3 inhibition. Carcinogenesis 2011; 32(6): 804-11.
[http://dx.doi.org/10.1093/carcin/bgr015] [PMID: 21289371]
[28]
De Laurentiis M, Cianniello D, Caputo R, et al. Treatment of Triple Negative Breast Cancer (TNBC): Current options and future perspectives. Cancer Treat Rev 2010; 36(Suppl. 3): S80-6.
[http://dx.doi.org/10.1016/S0305-7372(10)70025-6] [PMID: 21129616]
[29]
Nagakawa O, Murakami K, Yamaura T, et al. Expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) on prostate cancer cell lines. Cancer Lett 2000; 155(2): 173-9.
[http://dx.doi.org/10.1016/S0304-3835(00)00425-0] [PMID: 10822133]
[30]
Udayakumar TS, Chen ML, Bair EL, et al. Membrane type-1-matrix metalloproteinase expressed by prostate carcinoma cells cleaves human laminin-5 beta3 chain and induces cell migration. Cancer Res 2003; 63(9): 2292-9.
[PMID: 12727852]
[31]
Zhao M, Jiang B, Gao FH. Small molecule inhibitors of STAT3 for cancer therapy. Curr Med Chem 2011; 18(26): 4012-8.
[http://dx.doi.org/10.2174/092986711796957284] [PMID: 21824090]
[32]
Yu ZY, Huang R, Xiao H, et al. Fluacrypyrim, a novel STAT3 activation inhibitor, induces cell cycle arrest and apoptosis in cancer cells harboring constitutively-active STAT3. Int J Cancer 2010; 127(6): 1259-70.
[http://dx.doi.org/10.1002/ijc.25169] [PMID: 20087863]
[33]
Chun J, Choi RJ, Khan S, et al. Alantolactone suppresses inducible nitric oxide synthase and cyclooxygenase-2 expression by down-regulating NF-κB, MAPK and AP-1 via the MyD88 signaling pathway in LPS-activated RAW 264.7 cells. Int Immunopharmacol 2012; 14(4): 375-83.
[http://dx.doi.org/10.1016/j.intimp.2012.08.011] [PMID: 22940184]
[34]
Mi XG, Song ZB, Wu P, et al. Alantolactone induces cell apoptosis partially through down-regulation of testes-specific protease 50 expression. Toxicol Lett 2014; 224(3): 349-55.
[http://dx.doi.org/10.1016/j.toxlet.2013.11.002] [PMID: 24252419]
[35]
Siveen KS, Sikka S, Surana R, et al. Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors. Biochim Biophys Acta 2014; 1845(2): 136-54.
[PMID: 24388873]
[36]
Galoczova M, Coates P, Vojtesek B. STAT3, stem cells, cancer stem cells and p63. Cell Mol Biol Lett 2018; 23: 12.
[http://dx.doi.org/10.1186/s11658-018-0078-0] [PMID: 29588647]
[37]
Liu Y, Gao X, Wang S, et al. Cancer stem cells are regulated by STAT3 signalling in wilms tumour. J Cancer 2018; 9(8): 1486-99.
[http://dx.doi.org/10.7150/jca.23277] [PMID: 29721059]

Rights & Permissions Print Cite
Article Metrics
13
1
© 2024 Bentham Science Publishers | Privacy Policy